Security key
29014R202
- Security type / class
- Equity / COM NEW
- Total 13F shares
- 62
- Total 13F value
- $43
- Share change
- 0
- SEC-reported price per share
- $0.69
- Number of holders
- 1
Report period
Q2 2024
Institutions
1
Top holders
1
ELOX full security history
Ownership snapshot
Full 13F holder table
Eloxx Pharmaceuticals, Inc. SEC filings
Eloxx Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ELOX - Eloxx Pharmaceuticals, Inc. - COM NEW (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Pontifax Management 4 G.P...
Disclosed value leader
Pontifax Management 4 G.P...
Comparable rows
0/11
Latest evidence
31 Mar 2024
3/4/5
13F
Highest disclosed value: $443,946
11 rows are not safely comparable across share classes.
Showing 1-6 of 11 holder rows.
Quick read
Pontifax Management 4 G.P. (2015) Ltd. has the largest disclosed position value at $443.9K.
0 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Pontifax Management 4 G.P. (2015) Ltd.'s linked filing trail.
Disclosed position value
Top 4
Pontifax Management 4 G.P. (2015)...
$443.9K
Daniel E. Geffken
$36K
Neil S. Belloff
$30.3K
Towne Trust Company, N.A
$62
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Pontifax Management 4 G.P. (2015) Ltd. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$443,946
616,592 shares
|
— | 13 May 2021 |
| Daniel E. Geffken |
3/4/5
INTERIM CFO
|
—
denominator unverified
|
$36,000
50,000 shares
|
— | 29 Nov 2021 |
| Neil S. Belloff |
3/4/5
COO, GENERAL COUNSEL &CORP SEC
|
—
mixed-class rows
|
$30,293
42,074 shares
mixed-class rows
|
— | 30 Jul 2021 |
| Towne Trust Company, N.A |
13F
Company
|
—
denominator unverified
|
$62
62 shares
|
— | 31 Mar 2024 |
| Vijay Modur |
3/4/5
HEAD OF R&D
|
—
denominator unverified
|
—
30,000 shares
|
— | 25 Jan 2023 |
| Gadi Veinrib |
3/4/5
Director
|
—
denominator unverified
|
—
20,000 shares
|
— | 15 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
62
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
1
Q2 2024 holders
1
Holder diff
0
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|